Enhance your practice with CMEand tools that focus on the managementand treatment of patients with cancer.
Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Alexandria May, PharmD, BCPS
Shannon Raber, MS, CPNP, RN
Bridget Archambault, MSN, CPNP
A Patient-First Approach to Smoking Cessation and Lung Cancer Screening
Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM
Tobacco-Related Stigma as a Barrier to Lung Cancer Screening
A New Era of Hope in Non-Small Cell Lung Cancer Care
Geoffrey Oxnard, MD
Smarter Screening for Non-Small Cell Lung Cancer
Jobelle Baldonado, MD
Improving Adherence and Toxicity Monitoring in NSCLC Care
Raghava Reddy Induru, MD
Innovations Shaping the Future of Antibody-Drug Conjugates in NSCLC
Christine Bestvina, MD
Antibody-Drug Conjugates for NSCLC: How They Work and Who’s a Candidate
Laura Alder, MD
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Komal Jhaveri, MD, FACP
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Virginia Kaklamani, MD, DSc
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Oral SERDs and PROTACs in ER+/HER2− mBC: Testing Smarter, Treating Better
Integrating Molecular Testing into NSCLC Care
Managing Antibody-Drug Conjugate Toxicities in NSCLC Care
Key Questions Shaping Antibody-Drug Conjugate Use in NSCLC
The Importance of Multidisciplinary Coordination in NSCLC Care
The Evolving Role of Antibody-Drug Conjugates in NSCLC Care
Emerging Biomarker Research for NSCLC Antibody-Drug Conjugates
Moving Toward Biomarker-Driven Care in Bladder Cancer
Benjamin Garmezy, MD
What's Next for Urothelial Cancer Treatment?
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.